Core Viewpoint - The company, Shijiazhuang Pharmaceutical Group (石药集团), has announced the sale of a 30.0704% stake in Beijing Guoxin Huijin Co., Ltd. for RMB 230 million, which will allow the company to focus on its core business and optimize its financial structure [1]. Group 1 - The seller, Shijiazhuang Pharmaceutical Innovation Co., Ltd., is a non-wholly owned subsidiary of the company [1]. - The transaction is based on a comprehensive consideration of the seller's actual development status [1]. - The sale is expected to help optimize the seller's resource allocation and financial structure, allowing for a focus on core business and reduction of operational risks [1]. Group 2 - The target company primarily operates a full-media communication business platform, which is not part of the seller's core business [1]. - After the completion of the sale, the seller and the group will no longer hold any equity in the target company [1]. - This move is anticipated to contribute to the overall benefit of the group and facilitate high-quality development [1].

格隆汇2月26日丨新诺威(300765.SZ)公布，为优化资产结构，提高资产运营效率，石药创新制药股份有 限公司（简称"石药创新"或"公司"）于2026年2月25日与石药控股集团有限公司（简称"石药控股"）签 署了《股份转让协议》，拟将公司持有的北京国新汇金股份（维权）有限公司（简称"国新汇金"） 30.0704%股份以人民币2.3亿元的价格转让给石药控股。 ...

1月23日，新诺威涨5.02%，截至发稿，报39.77元/股，成交3.50亿元，换手率0.65%，总市值558.61亿 元。 截至发稿，成曦累计任职时间9年264天，现任基金资产总规模2369.54亿元，任职期间最佳基金回报 131.04%， 任职期间最差基金回报-67.89%。 刘树荣累计任职时间8年192天，现任基金资产总规模1276.84亿元，任职期间最佳基金回报194.12%， 任职期间最差基金回报-48.01%。 资料显示，石药创新制药股份有限公司位于河北省石家庄市栾城区张举路62号,香港湾仔港湾道18号中 环广场32楼3206室，成立日期2006年4月5日，上市日期2019年3月22日，公司主营业务涉及功能食品的 研发、生产与销售。主营业务收入构成为：功能食品及原料88.93%，生物制药8.91%，其他2.16%。 从新诺威十大流通股东角度 数据显示，易方达基金旗下1只基金位居新诺威十大流通股东。易方达创业板ETF（159915）三季度减 持132.53万股，持有股数786.8万股，占流通股的比例为0.63%。根据测算，今日浮盈赚取约1494.92万 元。 易方达创业板ETF（159915）成立日 ...

Group 1 - The core viewpoint of the article indicates that Shiyao Group's subsidiary, Shiyao Innovation, is expected to report a net loss attributable to shareholders of 170 million to 255 million yuan for the fiscal year 2025, compared to a profit of 53.7263 million yuan in the previous year [1] - The expected net loss after deducting non-recurring gains and losses is projected to be between 210 million and 315 million yuan, with the previous year's profit being 42.3419 million yuan [1] - The increase in research and development (R&D) expenses to approximately 1 billion yuan, a significant year-on-year increase, is a major factor affecting the current period's profit [1] Group 2 - In early November 2025, Shiyao Innovation completed the acquisition of an additional 29% minority stake in its subsidiary, Jushi Biotech, raising its ownership to 80% [2] - Due to significant investments in the research pipeline, Jushi Biotech is currently not profitable, and the increased ownership will amplify its impact on the consolidated financial statements of the company [2] - The company is actively consolidating its advantage in the functional raw materials business, particularly in caffeine products, although the gross margin and profitability of these products have slightly declined compared to the same period last year due to market factors [2]

Core Viewpoint - The company, Shiyao Group, is expected to report a significant net loss for its subsidiary, Shiyao Innovation, in 2025, contrasting with a profit in the previous year, primarily due to increased R&D investments and operational challenges [1][2]. Group 1: Financial Performance - Shiyao Innovation anticipates a net loss attributable to shareholders of 170 million to 255 million yuan for 2025, compared to a profit of 53.7263 million yuan in the previous year [1]. - The expected net loss, excluding non-recurring items, is projected to be between 210 million and 315 million yuan, down from a profit of 42.3419 million yuan in the prior year [1]. Group 2: R&D Investments - The company is significantly increasing its R&D expenditures, with total R&D costs expected to rise to approximately 1 billion yuan, marking a substantial year-on-year increase [1]. - Several products in the pipeline have made important progress, including four antibody drugs, six ADC products, and one mRNA vaccine receiving clinical trial approvals for the first time in 2025 [1]. Group 3: Subsidiary Developments - In early November 2025, Shiyao Innovation completed the acquisition of an additional 29% minority stake in its subsidiary, Jushi Biotech, raising its ownership to 80% [2]. - The increased stake in Jushi Biotech, which is currently not profitable due to high R&D investments, will have a more pronounced impact on the consolidated financial statements of Shiyao Innovation [2]. Group 4: Functional Raw Materials Business - Shiyao Innovation is working to strengthen its position in the functional raw materials sector, particularly in caffeine products, although the gross margin and profitability of these products have slightly declined compared to the previous year due to market factors [2].

数据显示，金元顺安基金旗下1只基金重仓新诺威。金元顺安医疗健康混合A类（007861）三季度增持 1.31万股，持有股数4.88万股，占基金净值比例为3.75%，位居第十大重仓股。根据测算，今日浮亏损 失约10.74万元。 金元顺安医疗健康混合A类（007861）成立日期2021年7月29日，最新规模3836.83万。今年以来收益 7.33%，同类排名1797/8840；近一年收益14.79%，同类排名5884/8094；成立以来亏损53.75%。 金元顺安医疗健康混合A类（007861）基金经理为陈铭杰、张海东。 截至发稿，陈铭杰累计任职时间2年82天，现任基金资产总规模7269.52万元，任职期间最佳基金回报 8.68%， 任职期间最差基金回报-24.12%。 张海东累计任职时间144天，现任基金资产总规模6.28亿元，任职期间最佳基金回报5.45%， 任职期间 最差基金回报-1.14%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 1月15日 ...

公司公告汇总关于控股子公司获得政府补助的公告 石药创新制药股份有限公司的控股子公司石药集团巨石生物制药有限公司于近日收到政府补助资金 6,000万元，占最近一个会计年度经审计的归属于上市公司股东净利润的10%以上且绝对金额超过100万 元。该补助为与收益相关的政府补助，与日常经营相关，不具有可持续性，资金已到账。该补助预计增 加公司2026年度利润总额，具体会计处理以审计结果为准。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自交易信息汇总：1月5日主力资金净流入1.02亿元，游资资金同步净流入，散户资金呈净流出 态势。 来自公司公告汇总：控股子公司石药集团巨石生物制药有限公司收到政府补助6,000万元，预计将 增加公司2026年度利润总额。 截至2026年1月5日收盘，新诺威(300765)报收于37.45元，上涨3.83%，换手率1.53%，成交量21.45万 手，成交额7.96亿元。 当日关注点 交易信息汇总资金流向 1月5日主力资金净流入1.02亿元；游资资金净流入5277.14万元；散户资金净流出1.55亿元。 ...

Group 1 - The core point of the news is that New Nuo Wei's stock price decreased by 1.22%, reaching 36.51 yuan per share, with a total market capitalization of 51.282 billion yuan [1] - New Nuo Wei is primarily engaged in the research, production, and sales of functional foods, with 88.93% of its revenue coming from functional foods and raw materials, 8.91% from biopharmaceuticals, and 2.16% from other sources [1] Group 2 - According to data, Pengyang Fund has a significant holding in New Nuo Wei, with its Pengyang Medical Health Mixed A Fund increasing its holdings by 123,500 shares to a total of 181,200 shares, representing 5.68% of the fund's net value [2] - The Pengyang Medical Health Mixed A Fund has achieved a year-to-date return of 27.83% and a one-year return of 26.14%, ranking 3388 out of 8087 and 3373 out of 8085 respectively [2] - The fund manager, Zhu Guoqing, has a tenure of 18 years and 289 days, with a total fund asset size of 862 million yuan, while the co-manager, Cui Jieming, has a tenure of 2 years and 62 days, managing assets of 147 million yuan [2]

近日，石药创新制药股份有限公司发布公告称，公司拟通过设立合资公司的方式，进一步加码创新生物医药领域布局，重点切入代谢类 疾病与 GLP-1 靶点相关赛道。根据公告，石药创新拟与中奇制药共同出资4.5亿元人民币，在石家庄设立石药集团润石生物科技（石家 庄）有限公司（暂定名，最终以市场监督管理部门核准登记为准）。 整理 | GLP1减重宝典内容团队 在本次合资安排中，石药创新将以自有资金出资1.575亿元，持股35%；中奇制药拟出资2.925亿元，持股65%。双方表示，合资公司设 立的背景在于国内健康意识持续提升、医疗支出稳步增长，以及临床需求和疾病诊疗水平不断提高，在此推动下，中国创新型代谢类药 物，尤其是 GLP-1 靶点相关产品，正进入快速发展阶段，具备较为明确的长期市场空间。 按照规划，合资公司将以创新型代谢类药物为核心方向，覆盖研发、产业化及商业化全链条，重点聚焦 GLP-1 靶点相关产品，主要面 向超重、肥胖及2型糖尿病等治疗领域，并在此基础上持续推进新型制剂研发和适应证扩展。 在资产与管线层面，合资公司设立后，将承接石药集团有限公司旗下全部 GLP-1 靶点及相关产品管线，涵盖从临床前研究、临床阶段 ...

Group 1 - The core point of the article highlights the recent decline in the stock price of New Nuo Wei, which fell by 5.36% to 37.44 CNY per share, with a trading volume of 245 million CNY and a turnover rate of 0.46%, resulting in a total market capitalization of 52.588 billion CNY [1] - New Nuo Wei, officially known as Shiyao Innovation Pharmaceutical Co., Ltd., is based in Shijiazhuang, Hebei Province, and was established on April 5, 2006. The company went public on March 22, 2019, and its main business involves the research, development, production, and sales of functional foods [1] - The revenue composition of New Nuo Wei is primarily from functional foods and raw materials at 88.93%, followed by biopharmaceuticals at 8.91%, and other sources at 2.16% [1] Group 2 - From the perspective of major fund holdings, data indicates that a fund under Jianxin Fund has a significant position in New Nuo Wei. Jianxin Medical Health Industry Stock A (008923) increased its holdings by 590,300 shares in the third quarter, bringing the total to 1.4473 million shares, which constitutes 4.74% of the fund's net value, ranking it as the seventh-largest holding [2] - Jianxin Medical Health Industry Stock A (008923) was established on December 28, 2021, with a current scale of 702 million CNY. Year-to-date returns are at 41.64%, ranking 1006 out of 4197 in its category; over the past year, returns are 40.12%, ranking 959 out of 4179; and since inception, returns are 39.64% [2]